cervical cancer
Conditions
Interventions
Group 2:concurrent chemoradiotherapy combined with adjuvant chemotherapy
Group 1:simple concurrent chemoradiotherapy
Sponsors
The Fourth Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.For the newly diagnosed patients, radiotherapy and chemotherapy were not performed before the start of the clinical trial; 2.Cervical cancer confirmed by histopathology; 3.FIGO stage IB3, IIA2, IIB-IVA patients in 2018; 4.There are lesions measurable according to RECIST 1.1 standard; 5.Aged 18-70 years; 6.PS score 0-1. 7.Serum hemoglobin >=100*10^9/L, blood platelet >= 100000/µL, absolute count of neutrophils>=1500/µL; 8.Serum creatinine = 60 ml/min; 9.Serum bilirubin 6 months.
Exclusion criteria
Exclusion criteria: 1.Patients with cognitive impairment; 2.Patients with any distant metastases; 3.Patients with any other malignancy within 5 years; 4.Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception; 6.Severe bone marrow dysfunction; 7.Patients with bleeding tendency; 8.Drug abusers or alcohol addicts; 9.Those who are known to have a third or fourth degree allergic reaction to any treatment in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| DMFS;LCR;acute toxicity;Long-term toxicity;living quality;ORR; | — |
Countries
China
Contacts
Public ContactFeng Chengjun
The Fourth Affiliated Hospital of Guangxi Medical University
Outcome results
None listed